AbbVie (ABBV) Revenue — Quarter Ended Dec 31, 2024
Revenue increased in the reporting quarter compared to both the prior quarter and the same quarter a year earlier. The sequential and year-over-year gains reflect continued growth in the company's top line.
Key takeaway
Quarter ended Dec 31, 2024 · FY2024 FY
Revenue increased in the reporting quarter compared to both the prior quarter and the same quarter a year earlier. The sequential and year-over-year gains reflect continued growth in the company's top line.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$15.1B
Revenue reported for this quarter.
Quarter-over-quarter
+4.4%
Change from the immediately preceding quarter.
Year-over-year
+5.6%
Change from the comparable year-ago quarter.
Trailing four quarters
$56.3B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Mar 31, 2024 | $12.3B | +0.7% |
| Jun 30, 2024 | $14.5B | +4.3% |
| Sep 30, 2024 | $14.5B | +3.8% |
| Dec 31, 2024 | $15.1B | +5.6% |
Revenue performance
The reported revenue rose from the immediately preceding quarter, extending the upward trend seen throughout the fiscal year. The year-over-year comparison also showed a higher result than the same period one year ago.
Quarterly comparison
Sequentially, revenue improved from the third quarter of the same fiscal year. On an annual basis, revenue exceeded the level reported for the final quarter of the prior fiscal year.
What to watch
Operating cash flow declined year over year, partly due to higher contingent consideration payments and working capital timing.